|
Express study: A trial in progress exploring the association between low level of genomic alteration and exceptional and unexpected response to targeted therapies in patients with solid tumors. |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bayer; Daiichi Sankyo; Epizyme; Lilly; Novartis; Roche |
Consulting or Advisory Role - Bayer; Daiichi Sankyo; Epizyme; Immune Design; Lilly; Roche |
Research Funding - AstraZeneca/MedImmune; Bayer; Merck Serono; Merck Serono; MSD Oncology; PharmaMar; Roche |
|
|
Research Funding - AstraZeneca (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline; Novartis; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb; Bristol-Myers Squibb (Inst); Ipsen (Inst); Merck (Inst); Novartis; Novartis (Inst); Pfizer (Inst); Roche (Inst) |
|
|
Consulting or Advisory Role - AstraZeneca; Novartis; Pfizer; Roche |
Research Funding - AstraZeneca (Inst); Novartis (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Novartis; pfizer; Roche |
|
|
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Cascadian Therapeutics (Inst); Lilly (Inst); MSD (Inst); Nektar (Inst); Novartis (Inst); Roche (Inst); Roche/Genentech (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Celgene; MSD; Novartis; Pfizer; Roche/Genentech |
|
|
Consulting or Advisory Role - AstraZeneca; Genomic Health; Illumina; Ipsen; MSD Oncology; MSD Oncology (Inst); Novartis; Pfizer; Puma Biotechnology; Roche/Genentech; Roche/Genentech (Inst) |
Research Funding - Roche (Inst) |
Travel, Accommodations, Expenses - Amgen; AstraZeneca |
|
|
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech/Roche; Lilly; Merck Serono; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Pierre Fabre; Takeda |
Consulting or Advisory Role - AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck Serono; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Takeda |
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Pierre Fabre (Inst); Roche/Genentech (Inst) |
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bristol-Myers Squibb; Roche/Genentech |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; Incyte; MSD; Novartis; Pfizer; Pierre Fabre; Roche |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD; Novartis; Roche |
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Novartis; Roche |
Research Funding - Bristol-Myers Squibb (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
Other Relationship - Avantis Medical Systems |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; Lilly; MSD Oncology; Novartis; Pfizer; Roche |
Research Funding - AstraZeneca; Bristol-Myers Squibb; Lilly; MSD Oncology; Novartis; Pfizer; Roche |
Travel, Accommodations, Expenses - AstraZeneca; Lilly; Novartis; Pfizer; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|